In the past, ARTKX is a fund I would have looked at. But given its declining relative performance over the years (going from 5* over the past
10 years to 4* over the past five, to 3* over the past three), I might have expected it to have reopened sooner.
The M* analysis notes that "the fund has historically fared best during sell-offs." This time though, YTD, it's behind its category average, -32.82% vs -30.49%.
The analysis also says that it blends quantitative and qualitative screens. If one wants a value-leaning international blend fund with a fair amount of EM (
10% - 20%), that uses both quantitative and qualitative processes, BRXAX is an alternative to consider.
It's also from a solid fund family (MFS), but it costs less and is much smaller in size ($250M vs. $
14B). The funds have comparable std dev, same 3 year risk rating, similar market cap and style (on the border between value and blend), identical Sharpe ratios, nearly identical market capture ratios.
It's done slightly worse, cumulatively over its nearly five year lifetime, -8.05% vs. -6.90%, though better over the past three years, -
14.7% vs. -
18.5%. YTD, BRXAX has slightly outperformed its category average at -29.5
1% (ARTKX has underperformed YTD). All figures are as of 3/
16/2020, using this
M* chart.
Given the similarity between these funds, I'd take a closer look at both before deciding to invest in ARTKX. Though if one wants a compact portfolio, ARTKX's has just 39 equity holdings vs.
135 for BRXAX. Or if one doesn't insist on on a value-leaning fund, it's not hard to find better performing foreign large cap funds.